<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812135</url>
  </required_header>
  <id_info>
    <org_study_id>EV71-1001-II-02</org_study_id>
    <nct_id>NCT01812135</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants</brief_title>
  <official_title>A Double-blind and Randomized, Phase II -02 Study With Inactivated EV71 Vaccines in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, phase II-02 clinical trial is to evaluate the safety and&#xD;
      immunogenicity of an inactivated EV71 vaccine with or without aluminum adjuvant&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Based on the previous study results, inactivated EV71 vaccine with aluminum adjuvant was&#xD;
    elected to be used for the efficacy Phase III study.&#xD;
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutralization antibody geometric mean titer in infants 28 days after immunization with 400U vaccine with or without aluminium hydroxide adjuvant</measure>
    <time_frame>2 months</time_frame>
    <description>Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus &gt;= 1:8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rates and severity of solicited and unsolicited adverse events in infants following immunization as a Measure of Safety and Tolerability</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Infection, Viral, Enterovirus</condition>
  <arm_group>
    <arm_group_label>Group 1: 400U EV71 vaccine without adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 400U EV71 vaccine without adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 400U EV71 vaccine with adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>400 U EV71 vaccine with adjuvant</intervention_name>
    <description>400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant</description>
    <arm_group_label>Group 1: 400U EV71 vaccine without adjuvant</arm_group_label>
    <arm_group_label>Group 2: 400U EV71 vaccine without adjuvant</arm_group_label>
    <arm_group_label>Group 3: 400U EV71 vaccine with adjuvant</arm_group_label>
    <other_name>EV71 vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males and females, aged from 6 to 11 months old Health is determined by&#xD;
             medical history, physical examination, laboratory examination and clinical judgment of&#xD;
             the investigator&#xD;
&#xD;
          2. Provided legal identification for the sake of recruitment.&#xD;
&#xD;
          3. Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed&#xD;
             consents.&#xD;
&#xD;
          4. Birth weight more than 2500 grams&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of Hand-foot-mouth Disease&#xD;
&#xD;
          2. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine&#xD;
&#xD;
          3. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory&#xD;
             difficulty, angioedema, or abdominal pain&#xD;
&#xD;
          4. Congenital malformations or developmental disorders, genetic defects, or severe&#xD;
             malnutrition&#xD;
&#xD;
          5. Epilepsy, seizures or convulsions history, or family history of mental illness&#xD;
&#xD;
          6. Autoimmune disease or immunodeficiency, or parents, brothers and sisters have&#xD;
             autoimmune diseases or immunodeficiency&#xD;
&#xD;
          7. History of asthma, angioedema, diabetes or malignancy&#xD;
&#xD;
          8. History of thyroidectomy or thyroid disease that required medication within the past&#xD;
             12 months&#xD;
&#xD;
          9. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions) or significant bruising or bleeding&#xD;
             difficulties with IM injections or blood draws&#xD;
&#xD;
         10. Asplenia, functional asplenia or any condition resulting in the absence or removal the&#xD;
             spleen&#xD;
&#xD;
         11. Acute illness or acute exacerbation of chronic disease within the past 7 days&#xD;
&#xD;
         12. Any history of immunosuppressive medications or cytotoxic medications or inhaled&#xD;
             corticosteroids within the past six months (with the exception of corticosteroid nasal&#xD;
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated&#xD;
             dermatitis)&#xD;
&#xD;
         13. History of any blood products within 3 months&#xD;
&#xD;
         14. Administration of any live attenuated vaccine within 28 days&#xD;
&#xD;
         15. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or&#xD;
             allergy treatment within 14 days&#xD;
&#xD;
         16. Axillary temperature &gt; 37.0 centigrade before vaccination&#xD;
&#xD;
         17. Abnormal laboratory parameters before vaccination&#xD;
&#xD;
         18. Any medical, psychiatric, social condition, occupational reason or other&#xD;
             responsibility that, in the judgment of the investigator, is a contraindication to&#xD;
             protocol participation or impairs a volunteer's ability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>11 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan-pin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GuangXi Center for Diseases Control and Prevention</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2013</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

